What Does TIGLUTIK Cost?

ITF Pharma is dedicated to providing support and services for those impacted by ALS. TIGLUTIK copay support helps ensure that people get financial assistance in accessing the treatment they need. Eligible patients pay no more than $50 per filled prescription of TIGLUTIK*.

* Eligibility and Restrictions

Offer is valid for each prescription fill for commercially insured patients where TIGLUTIK is covered. Offer is valid for patients aged 18 and older. Medicare, Medicaid, TRICARE, or patients of other federal or state programs are not eligible. ITF Pharma reserves the right to rescind, revoke, or amend this offer without notice. Offer good only in the USA, including Puerto Rico, at Anovo pharmacy. Void if prohibited by law, taxed, or restricted. This offer has no cash value and may not be used in combination with any other discount, coupon, rebate, free trial, or similar offer for the specified product. Maximum savings limit applies; patient out-of-pocket expense may vary.

Expand

Indication

TIGLUTIK is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS).

Important Safety Information

Contraindication

TIGLUTIK is contraindicated in patients with a history of severe hypersensitivity reactions to riluzole or to any of its components.

Warnings and Precautions

TIGLUTIK can cause liver injury and there have been cases of drug-induced liver injury, some of which were fatal, in patients taking riluzole. Asymptomatic elevations of hepatic transaminases have been reported and, in some patients, have recurred upon re-challenge with riluzole. Maximum increases in ALT occurred within 3 months after starting riluzole. Monitor patients for hepatic injury every month for the first 3 months of treatment, and periodically thereafter; TIGLUTIK should be discontinued if there is evidence of liver dysfunction, for example, elevated bilirubin. Use of TIGLUTIK with other hepatotoxic drugs may increase the risk for hepatotoxicity.

TIGLUTIK can cause neutropenia. Cases of severe neutropenia (absolute neutrophil count less than 500 per mm3) within the first 2 months of riluzole treatment have been reported. Advise patients to report febrile illnesses.

TIGLUTIK can cause interstitial lung disease, including hypersensitivity pneumonitis. Discontinue TIGLUTIK immediately if interstitial lung disease develops.

Adverse Reactions

The most common adverse reactions (incidence greater than or equal to 5% and greater than placebo) of TIGLUTIK were oral hypoesthesia (29%), asthenia (19%), nausea (16%), decreased lung function (10%), hypertension (5%), and abdominal pain (5%).

Coadministration of TIGLUTIK with strong or moderate CYP1A2 inhibitors, such as ciprofloxacin, enoxacin, fluvoxamine, methoxsalen, mexiletine, oral contraceptives, thiabendazole, vemurafenib, and zileuton, may increase the risk of TIGLUTIK-associated adverse reactions. 

Coadministration of TIGLUTIK with CYP1A2 inducers may result in decreased efficacy of TIGLUTIK.

Use in Specific Populations

Patients with mild or moderate hepatic impairment (Child-Pugh’s score A or B) had increases in AUC compared to patients with normal hepatic function. Thus, patients with mild or moderate hepatic impairment may be at increased risk of adverse reactions. Use of TIGLUTIK is not recommended in patients with baseline elevations of serum aminotransferases greater than 5 times the upper limit of normal or evidence of liver dysfunction.

Japanese patients are more likely to have higher riluzole concentrations, and thus may be at a greater risk of adverse reactions.

Please see accompanying prescribing information.

Intended for U.S. Residents Only

ITF Pharma logo

©2020 ITF Pharma Inc. All rights reserved.  TIGLUTIK is a trademark of ITALFARMACO SA 
TIGLMCH07/2020

850 Cassatt Road, Suite 350 
Berwyn, PA 19312 United States 
Medical/Product Inquiries: 844-763-1198 
ITF Pharma US Headquarters: 484-328-4964 
medicalinquiry@itfpharma.com 
www.itfpharma.com